VivoSeq
Other

Disc Degeneration

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Disc Degeneration is an early-stage landscape with 0 programs across 2 companies. The most active players are Sclnow Biotechnology Co., Ltd., Medtronic Spinal and Biologics.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sclnow Biotechnology Co., Ltd.

0 programs

PreclinicalM

Medtronic Spinal and Biologics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Unknown status1 · 25%
Suspended1 · 25%
Completed1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration
Unknown status·SSemmes-Murphey Foundation·N/A·NCT02379689·30 enrolled
SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration
Suspended·SSclnow Biotechnology Co., Ltd.·Phase 1·NCT06589271·20 enrolled
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration
Completed·DDiscGenics, Inc.·Phase 1·NCT03347708·60 enrolled
MDT-0123 Clinical Trial Targeting Patients Who Require Lumbar Vertebral Fusion in Japan
Recruiting·MMedtronic Spinal and Biologics·Phase 3·NCT07414745·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)